Table 1.
Patient characteristics (N = 10).
| Characteristic | N (%)X |
|---|---|
| Age, median (range), years | 65 (31–71) |
| Body mass index, median (range) | 33 (24–48) |
| FIGO Stage at Initial Diagnosis | |
| I | 2 (20) |
| II | – |
| III | 5 (50) |
| IV | 3 (30) |
| Histology | |
| Endometrioid | 7 (70) |
| Serous | 3 (30) |
| FIGO grade* | |
| I | – |
| II | 2 (29) |
| III | 5 (71) |
| Bone metastasis at diagnosis | 2 (20) |
| Bone metastasis at recurrence | 8 (80) |
| Mean time from diagnosis to bone metastasis (months) | 14.4 (0–44) |
| Extent of bone metastasis | |
| Single | 3 (30) |
| Multiple | 7 (70) |
| Concurrent extraosseous metastases | 10 (100) |
| Treatment of bone metastasis | |
| Radiation | 3 (3) |
| Chemotherapy | 1 (10) |
| Chemotherapy + radiation | 2 (20) |
| Concurrent chemoradiation, followed by chemotherapy | 1 (10) |
| Chemotherapy + radiation, followed by immunotherapy | 1 (10) |
| Chemotherapy + anti-angiogenesis | 1 (10) |
| Immunotherapy | 1 (10) |
| Overall survival, median (range), months | 11 (1–22) |
| Presence of microsatellite instability** | 7 (87.5) |
*
Endometrioid histology only, all other histologies represent high-grade disease.
**
N = 8 patients with immunohistochemistry or molecular tumor profiles available for review.
X
Values are number (percentage) unless indicated otherwise.